The randomized controlled trial found mobile PrEP and MOUD services did not improve medication use versus peer navigation alone among people who inject drugs, although mortality was lower.
August 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a...
In a multicenter dose de-escalation and expansion study of adults with HIV-related DLBCL, ibrutinib plus R-da-EPOCH showed manageable toxicity and clinical activity, with 3-year event-free and overall...
A phase 3 trial found that switching from bictegravir–emtricitabine–tenofovir alafenamide to once-daily bictegravir–lenacapavir maintained viral suppression in adults with HIV-1.
April 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
A large national database study presented at CROI 2026 in Denver, CO, reports that 5-year survival remains lower for people with HIV compared with people without HIV across most treatment modalities for...
A large US cohort study examined hepatitis B virus (HBV) monitoring practices and the risk of HBV reactivation and hepatitis flares during interruptions of tenofovir-containing antiretroviral therapy among...
In the phase 3 ACTG A5359 LATITUDE trial, investigators evaluated whether monthly, long-acting injectable cabotegravir plus rilpivirine could reduce regimen failure compared with standard oral...